Objectives: To determine the correlation between mean platelet count and grading of esophageal varices in patients of liver cirrhosis. Study Design: Cross Sectional study. Settings: Department of Medicine, DHQ Hospital (FMU) &AFM&DC Faisalabad. Period: 17th August 2019 to 16th February 2020. Material & Methods: A total of 105 patients liver cirrhosis with esophageal varices were included in the study according to the inclusion and exclusion criteria. For assessment of platelet count 2ml blood sample was sent to hospital pathology laboratory and it was reported by the pathologist. Upper GI endoscopy was performed by gastroenterologist for confirmation and grading of oesophageal varices. Results: In our study, it was observed that 04 (3.81%) patients had grade- I EV, 34 (32.38%) Grade-II, 39 (37.14%) Grade III, 15 (14.29%) Grade IV and 13 (12.38%) patients had Grade V esophageal varices. While correlating the mean platelet count and grading of esophageal varices in patients of liver cirrhosis, it was observed that the mean platelet count of the patients with Grade-I EV was 149000± 26000, platelet count in patients with Grade-II EV was 122000 ± 26000, platelet count in patients with Grade-III EV was 100000 ± 23000, platelet count in patients with Grade-IV EV was 98000 ± 26000 and platelet count in patients with Grade-V EV was 94000 ± 22000 with correlation r value of 0.370 and p-value of 0.0001 which is statistically significant. Conclusion: This study concluded that there is inverse correlation between mean platelet count and grades of esophageal varices in patients of liver cirrhosis.

Diabetes Mellitus is a very common metabolic disorder characterized by hyperglycemia and altered metabolism of lipids, proteins and carbohydrates due to absolute or relative insulin deficiency or insulin resistance. There is a close association between complications of Diabetes and Diabetic Dyslipidemias. The lowering of LDL levels with statins varies from 20 to 60% and greatest effects are seen with the most potent statins such as Atorvastatin, and Rosuvastatin in higher doses. Objectives: The objective of the study was; to compare Rosuvastatin with Atorvastatin in terms of mean change in LDL-C in patients of Diabetes Mellitus. Study Design: Randomized Control Trail. Setting: Department of Medicine DHQ Hospital, Faisalabad. Period: Six months from 01/10/2018 to 31/03/2019. Material & Methods: Results: A total of 160 cases (80 in each group) fulfilling the inclusive/exclusive criteria were enrolled to compare Rosuvastatin with Atorvastatin in terms of mean change in LDL-C in patients of Diabetes Mellitus. Mean LDL-C levels at baseline was recorded as159.61+1.22 in Group-A and 159.51+1.21 in Group-B, p value was calculated as 0.603 showing insignificant difference. Mean LDL-C after 6 weeks of treatment was recorded as129.11p+1.50 in Group-A and 129.89+2.23 in Group-B, p value was calculated as 0.01 showing significant difference. Mean change in LDL-C level after 6 weeks of treatment was recorded as 30.5+1.88 in Group-A and 29.63+2.57 in Group-B, p value was calculated as 0.01 showing a significant difference. The data was stratified for Age, Gender, Duration of Diabetes Mellitus and control of Diabetes Mellitus. Conclusion:  This study proves superiority of Rosuvastain over Atorvastatin in reducing LDL-C level in type 2 DM Patients.